David Regan of Sona Nanotech talks about developments in its unique gold nanorod technology
In this InvestorIntel interview with host Tracy Weslosky, Sona Nanotech Inc.‘s (CSE: SONA | OTCQB: SNANF) CEO David Regan talks about the promising properties of gold nanorod technology and the use of nanoparticles in the human body for advanced medical applications.
In the interview, which can also be viewed in full on the InvestorIntel YouTube channel (click here), David discusses the many potential applications of Sona’s nanoparticles and how its gold nanorods are uniquely created with no toxins and are more suited for medical uses such as implantation into the body. David also says he expects to receive shortly a new research and development study of this technology from Dr. Warren Chan’s Integrated Nanotechnology & Biomedical Sciences Laboratory at the University of Toronto.
David also talks about attracting world-class talent to Sona Nanotech’s board, including Neil Fraser, past chair of Medtech Canada, and Dr. Walter Strapps who served as Chief Scientific Officer of Gemini Therapeutics. They join Sona Nanotech director Mark Lievonen, former President of Sanofi Pasteur Limited.
Don’t miss other InvestorIntel interviews. Subscribe to the InvestorIntel YouTube channel by clicking here.
About Sona Nanotech Inc.
Sona Nanotech is a nanotechnology life sciences firm that has developed multiple proprietary methods for the manufacture of various types of gold nanoparticles. The principal business carried out and intended to be continued by Sona is the development and application of its proprietary technologies for use in multiplex diagnostic testing platforms that will improve performance over existing tests in the market. Sona Nanotech’s gold nanorod particles are CTAB (cetyltrimethylammonium) free, eliminating the toxicity risks associated with the use of other gold nanorod technologies in medical applications. It is expected that Sona’s gold nanotechnologies may be adapted for use in applications, as a safe and effective delivery system for multiple medical treatments, subject to the approval of various regulatory boards, including Health Canada and the FDA.
To learn more about Sona Nanotech Inc., click here
Disclaimer: Sona Nanotech Inc. is an advertorial member of InvestorIntel Corp.
This interview, which was produced by InvestorIntel Corp., (IIC), does not contain, nor does it purport to contain, a summary of all the material information concerning the “Company” being interviewed. IIC offers no representations or warranties that any of the information contained in this interview is accurate or complete.
This presentation may contain “forward-looking statements” within the meaning of applicable Canadian securities legislation. Forward-looking statements are based on the opinions and assumptions of the management of the Company as of the date made. They are inherently susceptible to uncertainty and other factors that could cause actual events/results to differ materially from these forward-looking statements. Additional risks and uncertainties, including those that the Company does not know about now or that it currently deems immaterial, may also adversely affect the Company’s business or any investment therein.
Any projections given are principally intended for use as objectives and are not intended, and should not be taken, as assurances that the projected results will be obtained by the Company. The assumptions used may not prove to be accurate and a potential decline in the Company’s financial condition or results of operations may negatively impact the value of its securities. Prospective investors are urged to review the Company’s profile on Sedar.com and to carry out independent investigations in order to determine their interest in investing in the Company.
If you have any questions surrounding the content of this interview, please contact us at +1 416 792 8228 and/or email us direct at firstname.lastname@example.org.